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nicely the historical data showing that women have always been re-
ported to have worse outcomes. So what is your hypothesis for this
change to equal outcome with men: is it better risk factor medical
management?
Dr Jeffrey Jim. I think within the past two decades there has
certainly been a difference in terms of patient selection, which we
cannot account for. I think everybody knows that medical manage-
ment has gotten signiﬁcantly better. When we compare the old
studies from 20 years ago, the best medical therapy was essentially
only aspirin and good blood pressure and glucose control. There
was no consideration of statins and, obviously, the newer-genera-
tion antiplatelet agents. So I think that patient selection is a little
bit different and medical management is very different as well.
Dr Richard Cambria (Boston, Mass). I wonder if your results
were corrected for pathology. I think you showed us that fully 25%
of the women in one of your subgroups were treated for recurrent
stenosis. And at least in the paradigm of angioplasty and stenting,
you would expect complications in that group to be signiﬁcantly
lower as a function of the fact that some of them, perhaps many,
were treated for intimal hyperplasia as opposed to degenerative pla-
que. So I wonder if the results have been corrected by throwing
out the restenosis patients?
Dr Jim. We did not throw them out per se but accounted for
disease etiology in our analysis. We did not have additional data
points, such as plaque characteristics, included in the data, but
we certainly accounted for the etiology of the disease.
Dr Cambria. Is it true that 25% of the women were treated
for recurrent stenosis, or was that only in the carotid angioplasty
and stenting (CAS) group?
Dr Jim. That was only the stenting group. There was only 1%
to 2% of the endarterectomy group that was treated for restenosis.
Dr Cambria. Well, I still think that with that percentage of
patients in theCAS that has to be corrected for in terms of comparing
complications, but appreciate your presentation of a lot of data.Dr David Rigberg (Los Angeles, Calif). You did mention the
selection bias. And I was wondering, from your data set, is there
any way to know what the percentage of men vs women under-
going any intervention was, so what the number was, so that
maybe what we are seeing is just fewer women undergoing a proce-
dure based on the type and level of disease they have?
Dr Jim. The way the registry works is every patient in each
individual center should be included. In our total study we had
about 10,000 patients, with about 40% being women. And if
you look at the different subgroups in terms of the stenting as
well as the endarterectomy, they were about the same; it was about
a 60/40 split.
Dr John Ricotta (Washington, D.C.). This is not the same
as a comparison, like as in ACAS (Asymptomatic Carotid Athero-
sclerosis Study) or the ACST (Asymptomatic Carotid Surgery
Trial) where you were looking at medical management vs surgical
management. So it is conceivable that these results, while they
don’t show a difference in surgical outcome, still do not prove
the hypothesis that for asymptomatic patients there is as much
beneﬁt for men as women. Can you comment on that?
Dr Jim. I think the hesitation to treating women comes from
two factors. One is the fact that there was a higher rate of perioper-
ative events, and the second one was that women tend to just have
fewer events on medical therapy. Our study essentially is able to
only address the ﬁrst part. We were able to compare men and
women essentially showing that they have equivalent surgical
outcomes. But we did not have data on treatment with optimal
medical therapy alone. And you are right, potentially, that is the
group that has the best results and certainly do not need
intervention.
Dr Ricotta. Did you have any data on the prevalence of the
use of patching in these patients, or was that not available?
Dr Jim. That is not available because some centers were
doing eversion endarterectomies so it is hard to separate those
patients out.
